Right Drug Dose Now Act of 2025

This bill aims to cut down on bad drug reactions by using gene-based information in everyday care. It tells the health department to update the national plan for preventing adverse drug events and report on progress, with a focus on how genes and medicines interact and how testing can help prevent harm. It also directs clear guidance for doctors, pharmacists, and other providers on when to consider gene-based testing, how to use it in medication decisions, when to involve genetics experts, and how to include this information when reporting drug side effects to the FDA’s system.

Electronic health records would be improved to flag, before a prescription is placed, when gene-based testing is recommended and when a patient’s genes may affect how a drug works. Guidance for these alerts must be updated at least twice a year as new drug labels and professional guidelines come out. The bill encourages easier reporting of side effects straight from medical records to the FDA, adds simple options for patients to report whether a side effect may be tied to a gene–drug issue, and calls for a federal study on adding gene–drug information to drug labels. It also requires a report on what upgrades EHRs need to better support this kind of evidence and testing info.

• Who is affected: Patients, doctors, pharmacists, nurses, and health IT/EHR systems.
• What changes: Updated national prevention plan; provider guidance on gene-based testing; smarter EHR alerts; simpler side‑effect reporting to the FDA; study on improving drug labels; and a report on EHR improvements .
• When: A report on the national plan is due within 180 days; guidance for EHR alerts is updated at least twice a year; progress on FDA reporting upgrades is due within one year .